As reported on Becker’s Hospital Review, the FDA has approved a first-of-its-kind pulmonary heart valve that can be enlarged after implantation, potentially allowing the device to accommodate a child’s growth and reduce the need for additional open-heart procedures.
The Autus Size-Adjustable Valve is intended for pediatric patients with congenital pulmonary valve disease. Unlike conventional replacement valves that remain a fixed size, Autus can be implanted at approximately 13 millimeters in diameter and later expanded to as much as 22 millimeters, a size comparable with an adult pulmonary valve.
The initial placement requires surgery. When a larger valve is needed as the patient grows, physicians can expand the existing device through a less-invasive transcatheter procedure using a balloon catheter. The approach could lessen the need for repeat open-heart operations associated with children outgrowing fixed-size valves.
FDA clearance was supported by a multicenter clinical study that enrolled 62 pediatric patients at 12 U.S. sites. Procedures were successfully completed in all participants, with no reported deaths, strokes or thrombotic events requiring treatment. At six months, data from the first 60 participants demonstrated acceptable blood-flow performance, with pulmonary regurgitation limited to mild or less.
Investigators reported three valve-frame fractures and reduced leaflet mobility in two patients, although the affected children did not have symptoms. Two participants who began to outgrow their implanted valves subsequently underwent successful catheter-based expansion without another surgery. The FDA noted that clinical experience with expanding the valve remains limited.
Autus also represents a materials milestone. Its valve leaflets are made with a polymer rather than animal-derived tissue, making it the first heart valve using polymeric leaflets to receive U.S. approval.
The potential patient population is significant. Congenital heart defects occur in roughly 1 in 100 U.S. births, while pulmonary valve stenosis and atresia together affect approximately 4,200 babies nationwide each year, according to CDC figures cited by the FDA. These abnormalities can restrict blood flow from the heart to the lungs, and some patients ultimately require pulmonary valve replacement.
The approval is also the first pediatric device approval to emerge from the FDA’s Total Product Life Cycle Advisory Program, which is intended to facilitate development of innovative medical devices while maintaining safety and effectiveness standards.
Edwards Lifesciences said patients in the pivotal study will continue to be monitored for 10 years, providing longer-term evidence on valve durability, performance and outcomes as children grow.
